Pre-made Lorukafusp benchmark antibody ( Whole mAb Fusion, anti-Ganglioside GD2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lorukafusp biosimilar, Whole mAb Fusion: Anti-Ganglioside GD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-322-1mg	1mg	Inquiry
GMP-Bios-ab-322-10mg	10mg	Inquiry
GMP-Bios-ab-322-100mg	100mg	Inquiry
GMP-Bios-ab-322-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lorukafusp biosimilar, Whole mAb Fusion: Anti-Ganglioside GD2 therapeutic antibody
INN Name	Lorukafusp
Target	Ganglioside GD2
Format	Whole mAb Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL
Year Proposed	2018
Year Recommended	2019
Companies	Lexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison
Conditions Approved	na
Conditions Active	Malignant melanoma;Neuroblastoma
Conditions Discontinued	na
Development Tech	na